Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes

Inclusion Criteria:

• Known DM2 (receiving lifestyle management and/or metformin and/or sulfonylurea
• Stable therapy for DM2 for the past 3 months
• All other medications and doses stable for past 3 months
• HbA1c 8.9% or lower (can be done in past 30 days)

• Known NASH based on the accepted American Gastroenterological Association Criteria:

  1. Alcohol consumption (< 10g/day in women and <20g/day in men)
  2. Cause of liver disease other than NAFLD (negative investigations for: viral hepatitis, iron overload, a-1 antitrypsin, ceruloplasmin, autoimmune disease)
  3. Liver histology demonstrating macrovesicular fatty change of hepatocytes, with evidence of steatohepatitis, manifested by the presence of Mallory Bodies, ballooning degeneration, lobular neutrophilic inflammation and perisinusoidal fibrosis. (If liver biopsy done within 2 years prior to screening for this trial, that biopsy will be reviewed to ensure it meets criteria for diagnosis).

Exclusion Criteria:

• Any contraindication for undergoing MRI
• Child class B or C cirrhosis
• Participation in another clinical trial
• Use of thiazoledinedione (rosiglitazone or pioglitazone) in past 6 months
• Current use of plavix
• Previous exposure to sitagliptin
• Prior history of pancreatitis
• History of anaphylaxis to another Canadian-marketed DPP-IV inhibitor (saxagliptin)
• Creatine clearance <30 ml/min
• Anaemia (haemoglobin < 110 mg/dL)
• Platelet count < 50 000 cells/mm3
• Known heart or kidney failure
• Comorbid condition that decreases natural life span (e.g. known cancer)
• Pregnant or breastfeeding or wishing to become pregnant in the next 6 months
• Current or past treatment with medications that can induce steatohepatitis (e.g. glucocorticoids, methotrexate, amiodarone etc.)